Understanding the Relevance of New FDA Initiatives and Policies and How They May Redefine the Life Sciences Industry in the Aftermath of COVID-19
Kurt R. Karst
Hyman, Phelps & McNamara, P.C. (Washington, DC)
Sidley Austin LLP (Washington, DC)
The COVID-19 Pandemic has impacted thousands of businesses and organizations around the world. This opening session will focus on the actions of the U.S. Food and Drug Administration to protect the public to ensure the public has access to safe food and medical supplies, as well as its impact on the pharmaceutical and biologics industries.